VEGF-A controls the expression of its regulator of angiogenic functions, dopamine D2 receptor, on endothelial cells.


Journal

Journal of cell science
ISSN: 1477-9137
Titre abrégé: J Cell Sci
Pays: England
ID NLM: 0052457

Informations de publication

Date de publication:
01 06 2022
Historique:
received: 22 11 2021
accepted: 05 05 2022
pubmed: 21 5 2022
medline: 3 6 2022
entrez: 20 5 2022
Statut: ppublish

Résumé

We have previously demonstrated significant upregulation of dopamine D2 (DAD2) receptor (DRD2) expression on tumor endothelial cells. The dopamine D2 receptors, upon activation, inhibit the proangiogenic actions of vascular endothelial growth factor-A (VEGF-A, also known as vascular permeability factor). Interestingly, unlike tumor endothelial cells, normal endothelial cells exhibit very low to no expression of dopamine D2 receptors. Here, for the first time, we demonstrate that through paracrine signaling, VEGF-A can control the expression of dopamine D2 receptors on endothelial cells via Krüppel-like factor 11 (KLF11)-extracellular signal-regulated kinase (ERK) 1/2 pathway. These results thus reveal a novel bidirectional communication between VEGF-A and DAD2 receptors.

Identifiants

pubmed: 35593650
pii: 275437
doi: 10.1242/jcs.259617
pmc: PMC9234670
pii:
doi:

Substances chimiques

Receptors, Dopamine D2 0
VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : R01 CA169158
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL131405
Pays : United States

Informations de copyright

© 2022. Published by The Company of Biologists Ltd.

Déclaration de conflit d'intérêts

Competing interests The authors declare no competing or financial interests.

Références

Nat Med. 2019 Apr;25(4):628-640
pubmed: 30833752
Am J Physiol Regul Integr Comp Physiol. 2014 Sep 15;307(6):R693-703
pubmed: 24990856
J Biol Chem. 2012 Apr 13;287(16):12723-35
pubmed: 22375010
Sci Rep. 2019 Nov 29;9(1):18002
pubmed: 31784669
Nat Rev Mol Cell Biol. 2016 Oct;17(10):611-25
pubmed: 27461391
Biomedicines. 2021 Mar 08;9(3):
pubmed: 33800198
Cancer Treat Rev. 2020 Jun;86:102017
pubmed: 32335505
Trends Cardiovasc Med. 2003 Jul;13(5):169-75
pubmed: 12837578
Cancer Res. 2004 Aug 15;64(16):5551-5
pubmed: 15313889
Nat Med. 2001 May;7(5):569-74
pubmed: 11329058
Clin Cancer Res. 2004 Jul 1;10(13):4349-56
pubmed: 15240521
J Am Soc Nephrol. 2015 Apr;26(4):876-87
pubmed: 25145928
J Thromb Haemost. 2005 Aug;3(8):1835-42
pubmed: 16102050
Int J Cancer. 2017 May 1;140(9):2150-2161
pubmed: 28152577
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
Biol Reprod. 2016 Apr;94(4):87
pubmed: 26935598
Br J Pharmacol. 2015 Jan;172(1):1-23
pubmed: 25671228
Reprod Sci. 2017 Aug;24(8):1129-1138
pubmed: 28372535
Am J Pathol. 2016 Sep;186(9):2262-70
pubmed: 27422612
Trends Biochem Sci. 1999 Jun;24(6):236-40
pubmed: 10366853
Endocrinology. 2010 Dec;151(12):5570-81
pubmed: 21047943
Surgery. 2002 Aug;132(2):259-67
pubmed: 12219021
Hum Reprod. 2021 Mar 18;36(4):850-858
pubmed: 33355352
J Clin Invest. 2008 Apr;118(4):1380-9
pubmed: 18340382
Nat Commun. 2020 Nov 6;11(1):5653
pubmed: 33159076
Biomedicines. 2021 Jan 22;9(2):
pubmed: 33499192
PLoS One. 2013;8(1):e53131
pubmed: 23372655
APMIS. 2004 Jul-Aug;112(7-8):496-507
pubmed: 15563312
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
JCI Insight. 2021 Aug 9;6(15):
pubmed: 34369383
Lab Invest. 2000 Jan;80(1):99-115
pubmed: 10653008
Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20730-5
pubmed: 22143796
J Diabetes Res. 2021 Feb 01;2021:7136869
pubmed: 33604390
Nature. 2005 Dec 15;438(7070):932-6
pubmed: 16355210
J Biol Chem. 1998 Oct 2;273(40):25929-36
pubmed: 9748269
Physiol Rev. 1998 Jan;78(1):189-225
pubmed: 9457173
Proc Natl Acad Sci U S A. 2011 May 10;108(19):7902-7
pubmed: 21464299
Cancer Prev Res (Phila). 2021 Jul;14(7):687-696
pubmed: 33846213
Nat Chem Biol. 2021 Jan;17(1):10-19
pubmed: 33328654
Mol Biol Rep. 2020 Dec;47(12):9689-9697
pubmed: 33170427
Nat Rev Clin Oncol. 2012 Feb 14;9(5):297-303
pubmed: 22330688
Cell Death Dis. 2021 Jul 29;12(8):749
pubmed: 34321458
Biochem Biophys Res Commun. 1992 Dec 15;189(2):824-31
pubmed: 1281999
Mol Oncol. 2015 Jan;9(1):270-81
pubmed: 25226814
Clin Cancer Res. 2008 Apr 15;14(8):2502-10
pubmed: 18413843

Auteurs

Chandrani Sarkar (C)

Department of Pathology, Ohio State University, Columbus, Ohio 43201, USA.
Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA.
Department of Pathology, University of South Alabama, Mobile, Alabama 36617, USA.
Cancer Biology Program, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36688, USA.
Department of Biochemistry & Molecular Biology, University of South Alabama, Mobile, Alabama 36688, USA.

Debanjan Chakroborty (D)

Department of Pathology, Ohio State University, Columbus, Ohio 43201, USA.
Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA.
Department of Pathology, University of South Alabama, Mobile, Alabama 36617, USA.
Cancer Biology Program, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36688, USA.
Department of Biochemistry & Molecular Biology, University of South Alabama, Mobile, Alabama 36688, USA.

Sandeep Goswami (S)

Department of Pathology, Ohio State University, Columbus, Ohio 43201, USA.
Department of Pathology, University of South Alabama, Mobile, Alabama 36617, USA.
Cancer Biology Program, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36688, USA.

Hao Fan (H)

Department of Pathology, Ohio State University, Columbus, Ohio 43201, USA.

Xiaokui Mo (X)

Department of Biomedical Informatics, Ohio State University, Columbus, Ohio 43210, USA.

Sujit Basu (S)

Department of Pathology, Ohio State University, Columbus, Ohio 43201, USA.
Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA.
Division of Medical Oncology, Department of Internal Medicine, Ohio State University, Columbus, Ohio 43210, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH